RhumbLine Advisers
THRD

RhumbLine Advisers’s Third Harmonic Bio THRD Stock Holding History

RhumbLine Advisers’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Sell
19,980
-287
-1% -$1.54K ﹤0.01% 3380
2025
Q4 		$109K Sell
20,267
-440
-2% -$2.37K ﹤0.01% 3433
2025
Q3 		$111K Sell
20,707
-12,965
-39% -$70.4K ﹤0.01% 3483
2025
Q2 		$183K Buy
33,672
+5,501
+20% +$27.4K ﹤0.01% 3270
2025
Q1 		$97.7K Sell
28,171
-751
-3% -$3.64K ﹤0.01% 3403
2024
Q4 		$298K Buy
28,922
+202
+0.7% +$2.52K ﹤0.01% 2989
2024
Q3 		$389K Buy
28,720
+119
+0.4% +$1.47K ﹤0.01% 2877
2024
Q2 		$372K Buy
28,601
+7,940
+38% +$98.2K ﹤0.01% 2867
2024
Q1 		$195K Buy
20,661
+888
+4% +$8.63K ﹤0.01% 3196
2023
Q4 		$217K Buy
19,773
+1,145
+6% +$9.07K ﹤0.01% 3148
2023
Q3 		$119K Buy
18,628
+1,841
+11% +$11.3K ﹤0.01% 3400
2023
Q2 		$80.7K Buy
16,787
+4,885
+41% +$23.3K ﹤0.01% 3576
2023
Q1 		$49K Buy
11,902
+1,267
+12% +$5.38K ﹤0.01% 2909
2022
Q4 		$46K Buy
+10,635
New +$178K ﹤0.01% 2958

Other funds holding THRD

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

RhumbLine Advisers's THRD Position: Q1 2026 in Review

RhumbLine Advisers reduced its Third Harmonic Bio (THRD) stake by 1.4% in Q1 2026, selling an estimated $1.54K and leaving 19,980 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #3380.

RhumbLine Advisers first reported a position in THRD in Q4 2022 and has held it in 14 quarters since. The position peaked at $389K in Q3 2024. 4 funds tracked by Wall St. Rank hold THRD as of Q1 2026.

  • RhumbLine Advisers held 19,980 shares of Third Harmonic Bio worth $107K as of Q1 2026.
  • RhumbLine Advisers sold 287 Third Harmonic Bio shares in Q1 2026, an estimated $1.54K.
  • Third Harmonic Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3380 holding.
  • RhumbLine Advisers first reported a position in Third Harmonic Bio in Q4 2022 and has held it in 14 quarters since.
  • RhumbLine Advisers's Third Harmonic Bio position peaked at $389K in Q3 2024.
  • 4 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.